A Phase Ib/II, Open Label, Single Arm, Multi-center, Dose Escalation Trial of Intravenous BI 836826 in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 12 Aug 2017
At a glance
- Drugs BI 836826 (Primary) ; Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 01 Aug 2017 Planned End Date changed from 15 Oct 2018 to 30 Jun 2019.
- 01 Aug 2017 Planned primary completion date changed from 2 Aug 2018 to 30 Jun 2019.
- 27 Jun 2016 Status changed from not yet recruiting to recruiting.